C-reactive protein in heart failure and sarcopenic obesity
https://doi.org/10.15829/1728-8800-2024-3887
EDN: BKOONP
Abstract
The variety of mechanisms of development and progression of heart failure (CHF) and sarcopenic obesity is reflected in changes in the concentrations of various biomarkers, one of which is high-sensitivity C-reactive protein (hsCRP). Its importance in the implementation of various stages of HF pathogenesis and its impact on the patient’s condition support the interest of researchers in studying this marker. It is known that HF is one of the pathogenetic factors leading to sarcopenia, which in turn aggravates the severity of these conditions. The purpose of this study is to analyze modern publications devoted to the role of hsCRP in the pathogenesis of HF and sarcopenic obesity, as well as to assess the relationship between hsCRP and the disease severity, prognosis for HF, sarcopenic obesity, and their combination.
About the Authors
V. I. Shevtsova
N.N. Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Voronezh
A. A. Pashkova
N.N. Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Voronezh
L. S. Palikhova
N.N. Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Voronezh
A. S. Korotyaeva
N.N. Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Voronezh
V. N. Salamatova
N.N. Burdenko Voronezh State Medical University
Russian Federation
Russian Federation
Voronezh
References
1. Drapkina ОМ, Dubolazova YuV, Eliashevich SО. The role of diet and physical activity in therapy of cardiovascular patients with normal ejection fraction. Cardiovascular Therapy and Prevention. 2017;16(2):73-80. (In Russ.) doi:10.15829/1728-8800-2017-2-73-80.
2. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013;34(7):512-9. doi:10.1093/eurheartj/ehs381.
3. Tokmachev RE, Budnevsky AV, Kravchenko AYa. The role of inflammation in the pathogenesis of chronic heart failure. Therapeutic archive. 2016;88(9):106-10. (In Russ.) doi:10.17116/terarkh2016889106-110.
4. Chumakova GA, Kuznetsova ТYu, Druzhilov МА, Veselovskaya NG. Visceral adiposity as a global factor of cardiovascular risk. Russian Journal of Cardiology. 2018;(5):7-14. (In Russ.) doi:10.15829/1560-4071-2018-5-7-14.
5. Kirkman DL, Bohmke N, Billingsley HE, et al. Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction. Front Endocrinol (Lausanne). 2020;11:558271. doi:10.3389/fendo.2020.558271.
6. Pacifico J, Geerlings MAJ, Reijnierse EM, et al. Prevalence of sarcopenia as a comorbid disease: a systematic review and meta-analysis. Exp Gerontol. 2020;131:110801. doi:10.1016/j.exger.2019.110801.
7. Izzo A, Massimino E, Riccardi G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors. Nutrients. 2021;13(1):183. doi:10.3390/nu13010183.
8. Clynes MA, Gregson CL, Bruyère O, et al. Osteosarcopenia: where osteoporosis and sarcopenia collide. Rheumatology (Oxford, England). 2021;60(2):529-37. doi:10.1093/rheumatology/keaa755.
9. Kim HS, Park JW, Lee YK, et al. Prevalence of sarcopenia and mortality rate in older adults with hip fracture. J Am Geriatr Soc. 2022;70(8):2379-85. doi:10.1111/jgs.17905.
10. Yeung SSY, Reijnierse EM, Pham VK, et al. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(3):485-500. doi:10.1002/jcsm.12411.
11. Mikaelyan AA, Varaeva YuR, Liskova YuV, et al. Sarcopenia and Chronic Heart Failure. Part 1. General Medicine. 2023;2:51-6. (In Russ.) doi:10.24412/2071-5315-2023-12879.
12. Crick D, Halligan S, Burgner D, et al. Comparison of stability of Glycoprotein Acetyls and high sensitivity C-reactive protein as markers of chronic inflammation. MedRxiv. 2023. doi:10.1101/2023.03.02.23286349.
13. Zvereva MD, Saburova OS, Melnikov IS, et al. Monomeric C-reactive protein in coronary artery disease. Complex Issues of Cardiovascular Diseases. 2020;9(2):45-52. (In Russ.) doi:10.17802/2306-1278-2020-9-2-45-52.
14. Utkina EA, Afanasyeva OI, Pokrovsky SN. C-reactive protein: pathogenetic characteristics and possible therapeutic target. Russian Journal of Cardiology. 2021;26(6):4138. (In Russ.) doi:10.15829/1560-4071-2021-4138.
15. Zhbanov KA, Salakheeva EYu, Sokolova IYa, et al. Neuregulin-1β, Biomarkers of Inflammation and Myocardial Fibrosis in Heart Failure Patients. Rational Pharmacotherapy in Cardiology. 2022;18(5):522-9. (In Russ). doi:10.20996/1819-6446-2022-09-05.
16. Khazova EV, Bulashova OV, Amirov NB. Is it necessary to determine highly sensitive C-reactive protein in patients with chronic heart failure: clinical and prognostic aspects. Bulletin of contemporary clinical medicine. 2022;15(4):54-9. (In Russ.) doi:10.33619/2414-2948/89/39.
17. Fyodorova TA, Ivanova YeA, Semenenko NA, et al. Clinical and Laboratory Aspects of Chronic Heart Failure in Patients with Metabolic Syndrome. Effective pharmacotherapy. 2019; 15(20):10-6. (In Russ.) doi:10.33978/2307-3586-2019-15-20-10-16.
18. Opotowsky AR, Valente AM, Alshawabkeh L. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank. Eur Heart J. 2018;39(34):3253-61. doi:10.1093/eurheartj/ehy362.
19. Pellicori P, Zhang J, Cuthbert J. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death, Cardiovasc Res. 2020;116(1):91-100. doi:10.1093/cvr/cvz198.
20. Örsçelik Ö, Özkan B, Arslan A. Relationship between intrarenal renin-angiotensin activity and re-hospitalization in patients with heart failure with reduced ejection fraction. Anatol J Cardiol. 2018;19(3):205-12. doi:10.14744/AnatolJCardiol.2018.68726.
21. Lena A, Anker MS, Springer J. Muscle wasting and sarcopenia in heart failure — the current state of science. Int J Mol Sci. 2020;21(18):6549. doi:10.3390/ijms21186549.
22. Wiedmer P, Jung T, Castro JP, et al. Sarcopenia — molecular mechanisms and open questions. Ageing Res Rev. 2021;65: 101200. doi:10.1016/j.arr.2020.101200.
23. Zarudskij AA. Sarcopenia and it's components in patients with systolic heart failure. Current problems of health care and medical statistics. 2020;2:132-43. (In Russ.) doi:10.24411/2312-2935-2020-00037.
24. Zuikova AA, Shevcova VI, Shevcov AN. Sarcopenic Obesity in Comorbid Patients. Journal of Clinical Practice. 2022;13(4):60-7. (In Russ.) doi:10.17816/clinpract112438.
25. Curcio F, Testa G, Liguori I, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211. doi:10.3390/nu12010211.
26. Carbone S, Billingsley HE, Rodriguez-Miguelez P, et al. Lean mass abnormalities in heart failure: the role of sarcopenia, sarcopenic obesity, and cachexia. Curr Probl Cardiol. 2020;45(11):100417. doi:10.1016/j.cpcardiol.2019.03.006.
27. Keng BMH, Gao F, Teo LLY, et al. Associations between skeletal muscle and myocardium in aging: a syndrome of "cardio-sarcopenia"? J Am Geriatr Soc. 2019;67(12):2568-73. doi:10.1111/jgs.16132.
28. Aimo A, Saccaro LF, Borrelli C, et al. The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease. Eur J Heart Fail. 2021;23(9):1458-67. doi:10.1002/ejhf.2298.
29. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393 (10191):2636-46. doi:10.1016/S0140-6736(19)31138-9.
30. Park CH, Do JG, Lee YT. Sarcopenic obesity associated with high-sensitivity C-reactive protein in age and sex comparison: A two-center study in South Korea. BMJ Open. 2018;8:e021232. doi:10.1136/bmjopen-2017-021232.
31. Safonova YuA, Toroptsova NV. Frequency and risk factors of sarcopenia in the elderly people. The clinician 2022;16(2):40-7. (In Russ.) doi:10.17650/1818-8338-2022-16-2-K661.
32. DuBrock HM, AbouEzzeddine OF, Redfield MM. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction. PloS Оne. 2018;13(8):e0201836. doi:10.1371/journal.pone.0201836.
33. Brinkley TE, Hsu FC, Beavers KM. Total and abdominal adiposity are associated with inflammation in older adults using a factor analysis approach. J Gerontol: Series A. 2012;67(10):1099-106. doi:10.1093/gerona/gls077.
34. Schrager MA, Metter EJ, Simonsick E. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 2007;102:919-25. doi:10.1152/japplphysiol.00627.2006.
35. Cesari M, Kritchevsky SB, Baumgartner RN. Sarcopenia, obesity, and inflammation — Results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr. 2005;82(1):428-34. doi:10.1093/ajcn/82.2.428.
36. Fukuda T, Bouchi R, Takeuchi T. Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: A retrospective observational study. Cardiovasc Diabetol. 2018;17:55. doi:10.1186/s12933-018-0700-5.
37. Franceschi C, Garagnani P, Vitale G. Inflammaging and 'garb-aging'. Trends Endocrinol Metab. 2017;28(3):199-212. doi:10.1016/j.tem.2016.09.005.
Supplementary files
What is already known about the subject?
- Sarcopenic obesity (SO) is common in patients with heart failure (HF).
- The level of high-sensitivity C-reactive protein, as a marker of systemic inflammation, tends to increase in both HF and SO and their combination.
What might this study add?
- Modern literature data confirm the possibility of using high-sensitivity C-reactive protein as a marker of the severity of the condition and progression of HF, including in patients with SO.
Review
For citations:
Shevtsova V.I., Pashkova A.A., Palikhova L.S., Korotyaeva A.S., Salamatova V.N. C-reactive protein in heart failure and sarcopenic obesity. Cardiovascular Therapy and Prevention. 2024;23(3):3887. (In Russ.) https://doi.org/10.15829/1728-8800-2024-3887. EDN: BKOONP
Views:
3016
Email this article 
